|
1
|
Singh N, Frey NV, Grupp SA and Maude SL:
CAR T cell therapy in acute lymphoblastic leukemia and potential
for chronic lymphocytic leukemia. Curr Treat Options Oncol.
17:282016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Swaminathan S, Klemm L, Park E,
Papaemmanuil E, Ford A, Kweon SM, Trageser D, Hasselfeld B, Henke
N, Mooster J, et al: Mechanisms of clonal evolution in childhood
acute lymphoblastic leukemia. Nat Immunol. 16:766–774. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Belver L and Ferrando A: The genetics and
mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer.
16:494–507. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Roberts KG and Mullighan CG: Genomics in
acute lymphoblastic leukaemia: Insights and treatment implications.
Nat Rev Clin Oncol. 12:344–357. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Conter V, Valsecchi MG, Buldini B,
Parasole R, Locatelli F, Colombini A, Rizzari C, Putti MC, Barisone
E, Lo Nigro L, et al: Early T-cell precursor acute lymphoblastic
leukaemia in children treated in AIEOP centres with AIEOP-BFM
protocols: A retrospective analysis. Lancet Haematol. 3:e80–e86.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cooper SL and Brown PA: Treatment of
pediatric acute lymphoblastic leukemia. Pediatr Clin North Am.
62:61–73. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kantarjian H, Stein A, Gökbuget N,
Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan
R, et al: Blinatumomab versus chemotherapy for advanced acute
lymphoblastic leukemia. N Engl J Med. 376:836–847. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pui CH, Yang JJ, Hunger SP, Pieters R,
Schrappe M, Biondi A, Vora A, Baruchel A, Silverman LB, Schmiegelow
K, et al: Childhood acute lymphoblastic leukemia: Progress through
collaboration. J Clin Oncol. 33:2938–2948. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Grohmann T, Penke M, Petzold-Quinque S,
Schuster S, Richter S, Kiess W and Garten A: Inhibition of NAMPT
sensitizes MOLT4 leukemia cells for etoposide treatment through the
SIRT2-p53 pathway. Leuk Res. 69:39–46. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartram I, Erben U, Ortiz-Tanchez J,
Blunert K, Schlee C, Neumann M, Heesch S and Baldus CD: Inhibition
of IGF1-R overcomes IGFBP7-induced chemotherapy resistance in
T-ALL. BMC Cancer. 15:6632015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Porter DL, Hwang WT, Frey NV, Lacey SF,
Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, et al:
Chimeric antigen receptor T cells persist and induce sustained
remissions in relapsed refractory chronic lymphocytic leukemia. Sci
Transl Med. 7:303ra1392015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jain N, Lamb AV, O'Brien S, Ravandi F,
Konopleva M, Jabbour E, Zuo Z, Jorgensen J, Lin P, Pierce S, et al:
Early T-cell precursor acute lymphoblastic leukemia/lymphoma
(ETP-ALL/LBL) in adolescents and adults: A high-risk subtype.
Blood. 127:1863–1869. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang J, Ding L, Holmfeldt L, Wu G,
Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, et
al: The genetic basis of early T-cell precursor acute lymphoblastic
leukaemia. Nature. 481:157–163. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Neumann M, Heesch S, Schlee C, Schwartz S,
Gökbuget N, Hoelzer D, Konstandin NP, Ksienzyk B, Vosberg S, Graf
A, et al: Whole-exome sequencing in adult ETP-ALL reveals a high
rate of DNMT3A mutations. Blood. 121:4749–4752. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Oda T, Muramatsu MA, Isogai T, Masuho Y,
Asano S and Yamashita T: HSH2: A novel SH2 domain-containing
adapter protein involved in tyrosine kinase signaling in
hematopoietic cells. Biochem Biophys Res Commun. 288:1078–1086.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lapinski PE, Oliver JA, Bodie JN, Marti F
and King PD: The T-cell-specific adapter protein family: TSAd, ALX,
and SH2D4A/SH2D4B. Immunol Rev. 232:240–254. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pegram HJ, Purdon TJ, van Leeuwen DG,
Curran KJ, Giralt SA, Barker JN and Brentjens RJ: IL-12-secreting
CD19-targeted cord blood-derived T cells for the immunotherapy of
B-cell acute lymphoblastic leukemia. Leukemia. 29:415–422. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shapiro MJ, Powell P, Ndubuizu A, Nzerem C
and Shapiro VS: The ALX Src homology 2 domain is both necessary and
sufficient to inhibit T cell receptor/CD28-mediated up-regulation
of RE/AP. J Biol Chem. 279:40647–40652. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Haferlach T, Kohlmann A, Wieczorek L,
Basso G, Kronnie GT, Béné MC, De Vos J, Hernández JM, Hofmann WK,
Mills KI, et al: Clinical utility of microarray-based gene
expression profiling in the diagnosis and subclassification of
leukemia: Report from the International microarray innovations in
leukemia study group. J Clin Oncol. 28:2529–2537. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gutierrez A, Kentsis A, Sanda T, Holmfeldt
L, Chen SC, Zhang J, Protopopov A, Chin L, Dahlberg SE, Neuberg DS,
et al: The BCL11B tumor suppressor is mutated across the major
molecular subtypes of T-cell acute lymphoblastic leukemia. Blood.
118:4169–4173. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wojtuszkiewicz A, Peters GJ, Van Woerden
NL, Dubbelman B, Escherich G, Schmiegelow K, Sonneveld E, Pieters
R, van de Ven PM, Jansen G, et al: Methotrexate resistance in
relation to treatment outcome in childhood acute lymphoblastic
leukemia. J Hematol Oncol. 8:612015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ishida T, Jo T, Takemoto S, Suzushima H,
Uozumi K, Yamamoto K, Uike N, Saburi Y, Nosaka K, Utsunomiya A, et
al: Dose-intensified chemotherapy alone or in combination with
mogamulizumab in newly diagnosed aggressive adult T-cell
leukaemia-lymphoma: A randomized phase II study. Br J Haematol.
169:672–682. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Iyer NS, Balsamo LM, Bracken MB and
Kadan-Lottick NS: Chemotherapy-only treatment effects on long-term
neurocognitive functioning in childhood ALL survivors: A review and
meta-analysis. Blood. 126:346–353. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Eiser C, Stride CB, Vora A, Goulden N,
Mitchell C, Buck G, Adams M and Jenney MEM; National Cancer
Research Institute Childhood Leukaemia Sub-Group and UK Childhood
Leukaemia Clinicians Network, : Prospective evaluation of quality
of life in children treated in UKALL 2003 for acute lymphoblastic
leukaemia: A cohort study. Pediatr Blood Cancer. 64:2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rodríguez-Lirio A, Pérez-Yarza G,
Fernández-Suárez MR, Alonso-Tejerina E, Boyano MD and Asumendi A:
Metformin Induces cell cycle arrest and apoptosis in drug-resistant
leukemia cells. Leuk Res Treatment. 2015:5164602015.PubMed/NCBI
|
|
27
|
Frismantas V, Dobay MP, Rinaldi A, Tchinda
J, Dunn SH, Kunz J, Richter-Pechanska P, Marovca B, Pail O, Jenni
S, et al: Ex vivo drug response profiling detects recurrent
sensitivity patterns in drug-resistant acute lymphoblastic
leukemia. Blood. 129:e26–e37. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee DA: Cellular therapy: Adoptive
immunotherapy with expanded natural killer cells. Immunol Rev.
290:85–99. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Idris SZ, Hassan N, Lee LJ, Md Noor S,
Osman R, Abdul-Jalil M, Nordin AJ and Abdullah M: Increased
regulatory T cells in acute lymphoblastic leukaemia patients.
Hematology. 21:206–212. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Locatelli F, Moretta F, Brescia L and
Merli P: Natural killer cells in the treatment of high-risk acute
leukaemia. Semin Immunol. 26:173–179. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Atkins MB: Interleukin-2: Clinical
applications. Semin Oncol. 29 (3 Suppl 7):S12–S17. 2002. View Article : Google Scholar
|
|
32
|
Terwijn M, Feller N, van Rhenen A, Kelder
A, Westra G, Zweegman S, Ossenkoppele G and Schuurhuis GJ:
Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic
blasts is predictive for outcome and level of residual disease in
AML. Eur J Cancer. 45:1692–1699. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cerny J, Yu H, Ramanathan M, Raffel GD,
Walsh WV, Fortier N, Shanahan L, O'Rourke E, Bednarik J, Barton B,
et al: Expression of CD25 independently predicts early treatment
failure of acute myeloid leukaemia (AML). Br J Haematol.
160:262–266. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Du S, Jia Y, Tang H, Sun Y, Wu W, Sun L,
Du J, Geng B, Tang C and Jin H: Immune regulation of hydrogen
sulfide in children with acute lymphoblastic leukemia. Chin Med J
(Engl). 127:3695–3699. 2014.PubMed/NCBI
|
|
35
|
Shen XH, Xu P, Yu X, Song HF, Chen H,
Zhang XG, Wu MY and Wang XF: Discrepant clinical significance of
CD28+CD8− and CD4+CD25high
regulatory T cells during the progression of hepatitis B virus
infection. Viral Immunol. 31:548–558. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Martkamchan S, Onlamoon N, Wang S,
Pattanapanyasat K and Ammaranond P: The effects of anti-CD3/CD28
coated beads and IL-2 on expanded T cell for immunotherapy. Adv
Clin Exp Med. 25:821–828. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Faganel Kotnik B, Grabnar I, Bohanec
Grabar P, Dolzan V and Jazbec J: Association of genetic
polymorphism in the folate metabolic pathway with methotrexate
pharmacokinetics and toxicity in childhood acute lymphoblastic
leukaemia and malignant lymphoma. Eur J Clin Pharmacol.
67:993–1006. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kodidela S, Suresh Chandra P and Dubashi
B: Pharmacogenetics of methotrexate in acute lymphoblastic
leukaemia: Why still at the bench level? Eur J Clin Pharmacol.
70:253–260. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Park E, Gang EJ, Hsieh YT, Schaefer P,
Chae S, Klemm L, Huantes S, Loh M, Conway EM, Kang ES, et al:
Targeting survivin overcomes drug resistance in acute lymphoblastic
leukemia. Blood. 118:2191–2199. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lopez-Lopez E, Gutierrez-Camino A,
Bilbao-Aldaiturriaga N, Pombar-Gomez M, Martin-Guerrero I and
Garcia-Orad A: Pharmacogenetics of childhood acute lymphoblastic
leukemia. Pharmacogenomics. 15:1383–1398. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ansari M, Sauty G, Labuda M, Gagné V,
Laverdière C, Moghrabi A, Sinnett D and Krajinovic M: Polymorphisms
in multidrug resistance-associated protein gene 4 is associated
with outcome in childhood acute lymphoblastic leukemia. Blood.
114:1383–1386. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xin N, Fen Z, Li C, Yan X and Runming J:
Intracranial hemorrhage following oral low-dose methotrexate after
multiple toxicities caused by high-dose methotrexate in childhood
acute lymphoblastic leukemia. Front Pharmacol. 10:10722019.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gervasini G and Mota-Zamorano S: Clinical
implications of methotrexate pharmacogenetics in childhood acute
lymphoblastic leukaemia. Curr Drug Metab. 20:313–330. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gonen N and Assaraf YG: Antifolates in
cancer therapy: Structure, activity and mechanisms of drug
resistance. Drug Resist Updat. 15:183–210. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kager L, Cheok M, Yang W, Zaza G, Cheng Q,
Panetta JC, Pui CH, Downing JR, Relling MV and Evans WE: Folate
pathway gene expression differs in subtypes of acute lymphoblastic
leukemia and influences methotrexate pharmacodynamics. J Clin
Invest. 115:110–117. 2005. View Article : Google Scholar : PubMed/NCBI
|
